The industry shaping 2021 agenda

The new infrastructure of Patient Centricity

00:00am – 00:00am (ZONE)

Panel:Embed the lived experience into your company’s DNA - change the hiring paradigm to achieve true patient centricity

  • See how embedding the patient, caregiver and HCP lived experience in your organization’s permanent workforce enables actionable patient-focused activities company-wide.
  • Move beyond traditional hiring criteria to prioritize lived experience over qualification and certification in certain patient advocacy roles and review committees - how and why
  • How embedding the HCP voice in pre-clinical provides vital understanding of HCP processes, patient subgroups, improved healthcare data utilization and commercial launch strategy.

Angela Colon-Mahoney VP People and Business Services Otsuka

Heather Dean VP, US Hematology Franchise Head Takeda

Wendy Erler Head of Patient Experience Alexion

Moderator: Gokul Gopalan VP, Global Medical Affairs Vertex

00:00am – 00:00am (ZONE)

The new infrastructure of patient-centricity

  • Hear successful, top-down approaches for reshaping your company infrastructure, to be patient-centric to the core
  • Make the patient perspective a fully actionable resource that can be shared and tracked seamlessly cross-business
  • Learn the change management requirements at all levels, needed to make infrastructural evolution happen

Anthony Yanni SVP and Global Head Patient Centricity Astellas Pharma

Patient-centric through diversity

00:00am – 00:00am (ZONE)

The FDA: Driving diversity in clinical data

  • Learn why and how the FDA is placing a greater focus on clinical trial data diversity when assessing drug approvals
  • Understand the industry expectations with the FDA guidance on Enhancing the Diversity of Clinical Trial Populations
  • Hear the FDA perspectives on what satisfactory trial data looks like
  • How patient listening sessions and patient committees are forming regulation around diversity and inclusion in clinical trial data
  • How the FDA can be a partner to enable easy access to epidemiology and disease information, while pushing inclusive clinical research

00:00am – 00:00am (ZONE)

Panel:Diversity, inclusion and equity outside of clinical trial data: A vital step for patient-centric front-runners

  • Discuss the critical need for diversity in pharma’s patient committees, patient advocacy partnerships and lived experience representatives - particularly in disease areas where race, gender, age, location, and socioeconomic factors greatly impact the patient journey
  • Identify “Health Deserts” for your disease area and develop a thorough inclusion strategy for these locations. Work with patient leaders, community leaders and advocacy groups to engage, educate, listen to their needs and build trust
  • Mindfully embed the voice of patient diversity and inclusion within the organization by hiring and training patients to be a part of your workforce
  • Showcase a truly patient-first approach by working with patient advocacy groups that hold pharma, themselves and other advocacy groups accountable to diversity, inclusion and equity

Christoph Koenen EVP & Chief Medical Officer Otsuka

CVS Health tbc

Moderna tbc

Johnson & Johnson tbc

New players have entered the game

00:00am – 00:00am (ZONE)

A new player in decentralized trials: Pharmacies’ role in creating a seamless patient experience

  • During the Covid vaccination trials, pharmacies got stuck in and offered up their stores. Now they’re working on rapidly expanding their offering to a multitude of other disease areas.
  • As a new stakeholder in decentralised trials, pharmacies could provide pharma with access to swathes of “heath desserts”, underrepresented patient populations and remove barriers to inclusion.
  • Hear how one pharmacy is taking on the huge task of creating infrastructure and digital frameworks (partnering with tech providers) from scratch to ensure data and outcomes seamlessly transfer between “sponsors” (pharma), sites, CROs and an excellent patient experience is at the forefront.

CVS Health tbc

00:00am – 00:00am (ZONE)

The growing role of PROA in collaboratively minimizing patient fatigue

  • Understand the growing importance of PROs in drug development, from R&D through post-launch, and implement an effective strategy for PROAs
  • Work with regulators to address strict guidance around patient surveys and amendment flexibility by disease area, to reduce the length and irrelevance of survey questions on certain patient populations

Embed equity into clinical trial protocols and achieve inclusive patient journeys

00:00am – 00:00am (ZONE)

Panel:Overcoming site barriers in trial enrolment for underrepresented populations

  • Work smart with clinical trial sites to ensure data and intelligence shared for trial site selection reflects underrepresented patient communities proportionate to the diseased patient population
  • Understand the patient voice to learn about the patient burden of trial participation and provide flexible options to reduce the burden
  • Track and monitor trial enrolment in real-time and work with trail sites to remove operational barriers that may impede diverse enrolment
  • Develop a robust trial decentralization plan, and evolve hybrid and virtual trial design to enable better access to home testing kits, home visits, PROs and telemedicine for groups in less accessible locations
  • Embed a diverse range of patient voices in trial protocol design to understand inclusion determinants and eradicate barriers before they arise

Elizabeth George Clinical Trial Diversity Leader, Innovation, Digital Clinical Trials Strategist GlaxoSmithKline

Dellann Elliott Mydland President & Chair EndBrainCancer Initiative

EMD Serono tbc

Moderator: Maimah Karmo President and CEO Tigerlily Foundation

00:00am – 00:00am (ZONE)

Case study:Why no strings attached patient education and engagement is essential for real progress in clinical trial enrolment diversity

  • Learn how a leading pharma company are reaching out to underrepresented patient communities with “no strings attached” awareness campaigns, to build greater trust and elevate the community discussion around clinical trials for industry
  • The need for a collective effort across industry to put business competitiveness aside to change the status-quo

Staci Hargraves VP R&D Portfolio Management Janssen

00:00am – 00:00am (ZONE)

A new (but old) Standard of Care: Pharma’s role in making trials accessible

  • Ensure your Standard of Care offering is appropriate, sufficient and well informed against insurance options available to your patient populations, with inclusion and health equity at the forefront.
  • Develop a communications plan that is concise and easily digestible for your target patients, and work with community leaders, patient leaders and patient groups to ensure your Standard of Care offering is widely known."

Monique C. Gore-Massy Global Lupus Patient Advocate Lupus Foundation of America COVID-19 Global Rheum Alliance

Boehringer Ingelheim tbc

Use behavior analysis and real patient perspectives to provide genuine clinical value

00:00am – 00:00am (ZONE)

Use behavior-based insights from R&D across the entire product lifecycle

  • Explore how R&D processes and strategy around behavioral science can be incorporated across all business units to improve patient engagement and the patient journey.
  • Develop a feedback mechanism that seamlessly feeds R&D insights into other teams.
  • Learn how to utilize data from wearable devises and PROs to determine patient behavioral predictions and optimize touchpoints.

00:00am – 00:00am (ZONE)

Set new treatment milestones and markers of success, determined by the patient lived experience

  • Obtain critical patient feedback in preclinical R&D to fully understand what progress and success looks like to patients in specific disease categories
  • Formulate a product R&D and clinical specification that adheres to patient-informed treatment milestones, large and small - such as pain reduction, better sleep, and fewer drug side-effects.
  • Develop a robust and all-encompassing milestone strategy for diseases where there are multiple symptoms (such as in Parkinson’s) and therefore often individual markers for success

Rebecca Vermuelen VP Patient & Society Strategy Product Development, Head of Healthcare and Patient Partnership Teams Roche

Addressing pharma’s “one foot in the grave” approach to digital patient engagement

00:00am – 00:00am (ZONE)

Panel:Get with the times: Engage a rising tide of next generation patient influencers and social media users

According to a recent survey by WEGO Health, when an influencer shares medical condition information from a pharma company, 9 out of 10 patients will ask their doctor about it.

  • Gain an understanding of patient influencer types such as rising-influencers, nano-influencers and micro-influencers, their various channel touchpoints with patient groups and how pharma can work with them most effectively.
  • Explore commonly talked about condition categories and specific conditions on social media, as well as the inherent intersectionality of topics in terms of patient influencer advocacy.
  • Address why a robust patient influencer strategy is critical now. The importance and worth of patient influencers have grown exponentially during the last year and pharma’s commercial teams must adapt and upskill to remain in touch with their core patient needs.

00:00am – 00:00am (ZONE)

Engage patients post-pandemic: Upskill your commercial workforce now to provide preferred and valuable interactions in the “new normal”

  • Evolve the skillset of your commercial team to be fully equipped for hybrid engagement strategies, adapted to new patient interaction preferences.
  • Find novel ways to build meaningful, lasting relationships with patient advocacy groups and patient leaders in a post-pandemic digital world.
  • Upskill your commercial workforce to turn social media likes, connections, followers, and shares into engagements that provide true value to patient groups.

00:00am – 00:00am (ZONE)

Realize an inclusive, hybrid patient interaction model: A holistic look at what we’ve gained and what we’ve lost through the pandemic

  • Gain patient feedback on key benefit areas relating to virtual physician-patient engagements in 2020/21.
  • Consider the shift to virtual on patient populations that cannot obtain smartphones, laptops and other vital devices for accessing care, and pave the way for equity and inclusion in future patient engagement models.
  • Devise next actionable steps for developing a patient care model that gives patients disease-appropriate options relating to how they interact with pharma and physicians.

Bryn Jones Global Lead, Patient Affairs ViiV Healthcare

00:00am – 00:00am (ZONE)

The evolution of telemedicine: Move beyond face-to-face meeting replication to improve care and find new tangible insights

  • Telemedicine served its purpose well during the pandemic and there is no doubt that it is here to stay, but how can the healthcare system now innovate past the Zoom call?
  • Identify new capability requirements across your organization and upskill HCPs to effectively conduct live procedures using video call
  • Establish a framework for automated telemedicine, and determine what innovation is needed in terms of its integration with surrounding care platforms.
  • Understand the opportunity for data and information auto-capture inside VTCs, and how this could be turned in to tangible patient-informed development

Diversifying commercial’s place in the new patient-centric equation

00:00am – 00:00am (ZONE)

Panel:Diversifying clinical trials: commercial’s critical seat at the table, defined

  • Hear from commercial leaders involved in research, development and trial design on how having a seat at the table directly benefits their commercial success post-launch.
  • Discuss how a cross-functional approach to diversifying clinical trials has been proven to reduce the risk of FDA approval challenges, challenging post-marketing commitments and loss of revenue.
  • Develop long-term, ongoing meaningful relationships with patient leaders to shape effective, patient-first launch strategies that reach and truly benefit underrepresented patient communities.

Elizabeth George Clinical Trial Diversity Leader, Innovation, Digital Clinical Trials Strategist GlaxoSmithKline

Mark Plinio Chief Commercial Officer Evelo Biosciences

00:00am – 00:00am (ZONE)

Work with patients to be a meaningful channel of lived experience through storytelling

  • Work closely with patients to embed real life stories in every piece of product or educative communication.
  • Create relatable marketing campaigns that resonate with what patients value most in a treatment and match their expectations of progress or success, based on lived experience.
  • Develop a diverse and close network/ patient coalition via patient leaders, advocacy groups and influencers to access a widely inclusive range of genuine patient anecdotes.
  • Demonstrate an appropriate approach to inclusive storytelling, based on disease specific patient diversity analysis.

00:00am – 00:00am (ZONE)

Transition to long-term patient-pharma partnerships from commercialization to post-product launch

  • Look at what commercial teams can do better to maintain partnerships developed in R&D and clinical development phases and ensure the patient voice remains prevalent post-commercialization
  • Learn from biopharma and biotech companies creating tight-knit patient relationships that last the commercial test of time
  • Discuss common barriers to patient engagement with commercial teams and ways to ensure patient exchanges are deemed non-transactional post-launch

Victoria DiBasio Global Head, Patient Informed Development & Health Value Translation Sanofi

Vanina Laurent-Ledru VP and Head, Global Public Affairs Sanofi Genzyme

Eric Racine VP & US Country Head, Public Affairs & Patient Advocacy Sanofi